ALPHA 1-ANTITRYPSIN DEFICIENCY (AATD)
Clinical trials for ALPHA 1-ANTITRYPSIN DEFICIENCY (AATD) explained in plain language.
Never miss a new study
Get alerted when new ALPHA 1-ANTITRYPSIN DEFICIENCY (AATD) trials appear
Sign up with your email to follow new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY (AATD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene-Editing shot aims to fix rare lung and liver disease
Disease control Recruiting nowThis early-stage trial tests a new gene-editing medicine called TSRA-196 in 72 adults with a severe form of alpha-1 antitrypsin deficiency (the PiZZ genotype) who have lung or liver problems. The treatment is given by IV infusion and aims to raise levels of a protective protein. …
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY (AATD)
Phase: PHASE1, PHASE2 • Sponsor: Tessera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Hidden gene behind breathlessness? study tests link to rare lung condition
Diagnosis Recruiting nowThis study is looking at whether a genetic condition called Alpha-1 antitrypsin deficiency (AATD) is more common in people who have shortness of breath and signs of airway blockage on breathing tests. Researchers will measure AAT levels and check for related gene mutations in 734…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY (AATD)
Sponsor: Muğla Sıtkı Koçman University • Aim: Diagnosis
Last updated Jun 26, 2026 16:36 UTC